Endocrinology 1981-07-01

19-Nor progesterone is a mineralocorticoid agonist.

J W Funder, W R Adam

Index: Endocrinology 109(1) , 313-5, (1981)

Full Text: HTML

Abstract

19-Nor progesterone (19-nor P) has previously been shown to have a approximately 3-fold higher affinity for mineralocorticoid receptors than progesterone (P), its C-19 methylated parent steroid; in contrast, 19-nor aldosterone has less than 1% the mineralocorticoid receptor affinity of aldosterone. In the present study we have compared P and 19-nor P, in terms of their mineralocorticoid activity in an adrenalectomized rat urinary K+/Na+ bioassay system. Progesterone, as previously has been shown, is a mineralocorticoid antagonist with no agonist activity. In contrast, 19-nor progesterone is a full mineralocorticoid agonist, with no discernible antagonist activity. Loss of the C19 methyl is thus followed by profound changes in mineralocorticoid activity (aldosterone: agonist to inactive; progesterone: antagonist to agonist). In the light of the recent demonstration of C19 demethylation by the kidney, such changes in mineralocorticoid activity may be implicated in currently unexplained syndromes of sodium retention.


Related Compounds

Related Articles:

Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay.

2008-05-01

[J. Steroid Biochem. Mol. Biol. 110(1-2) , 39-47, (2008)]

The blood pressure and metabolic effects of 19-nor-deoxycorticosterone and 19-nor-progesterone in sheep.

1984-01-01

[Clin. Exp. Hypertens. A. 6(9) , 1591-600, (1984)]

The pharmacology of nomegestrol acetate.

2012-04-01

[Maturitas 71(4) , 345-53, (2012)]

Interaction of new 19 nor progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors.

1986-01-01

[J. Pharmacol. 17(4) , 699-706, (1986)]

19-Nor-corticosteroids in experimental and human hypertension.

1982-01-01

[Clin. Exp. Hypertens. A. 4(9-10) , 1851-67, (1982)]

More Articles...